Carl Zeiss Meditec AG

As of December 31, 2025, Carl Zeiss Meditec AG carries a market capitalization of 3.09B, placing it among publicly traded companies globally. Its enterprise value stands at 3.09B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Carl Zeiss Meditec AG's next confirmed earnings release is scheduled for December 10, 2026.

As of December 31, 2025, Carl Zeiss Meditec AG has 81.67M shares outstanding.

As of December 31, 2025, Carl Zeiss Meditec AG trades at a trailing price-to-earnings ratio of 28.94.

As of December 31, 2025, Carl Zeiss Meditec AG trades at an EV/EBITDA multiple of 16.91 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.51 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 16.91 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Carl Zeiss Meditec AG trades at an EV/FCF ratio of 12.18, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 3.09B versus a market cap of 3.09B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of December 31, 2025.

These figures cover the twelve months ended December 31, 2025. The company generates approximately 356,456.15 in revenue per employee across its workforce of 5,757.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended December 31, 2025, Carl Zeiss Meditec AG recorded 43.30M in income tax expense. That works out to an effective tax rate of 27.62, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 156.78M, leaving 112.29M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 19, 2026, Carl Zeiss Meditec AG's stock has declined approximately 21.38% over the past 52 weeks.

Over the twelve months ended December 31, 2025, Carl Zeiss Meditec AG generated 2.05B in revenue and converted that into 112.29M in net income, yielding earnings per share of 1.32. EBITDA reached 182.81M, while operating income came in at 182.81M.

Carl Zeiss Meditec AG produced 235.41M in operating cash flow over the twelve months ended December 31, 2025.

Over the twelve months ended December 31, 2025, Carl Zeiss Meditec AG posted a gross margin of 52.19, reflecting its pricing power and cost economics. The operating margin of 8.91 and net profit margin of 5.47 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2025. Free cash flow yield stands at 7.24, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 5.30, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Carl Zeiss Meditec AG shareholders.

Carl Zeiss Meditec AG's most recent stock split took place on October 24, 2006.